Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor

publication date: Aug 11, 2023

Shanghai Antengene out-licensed China commercialization rights for its XPO1 inhibitor, an approved therapy for multiple myeloma in China, to Hansoh Pharma in a deal worth up to $101 million in upfront and milestone payments. Antengene will continue to conduct all development work of Xpovio®, including distribution. Hansoh will be responsible for commercialization for which it will charge a service fee based on sales. Antengene will be eligible to receive $28 million in upfront payments and $73 million in milestones, plus it will record revenues from the drug. Hansoh Group is based in Shanghai. More details....

Stock Symbols: (HK: 6996) (HK: 3692)

Share this with colleagues: